128 related articles for article (PubMed ID: 38465788)
1. Dupilumab prevents nasal epithelial function alteration by IL-4 in vitro: Evidence for its efficacy.
Fieux M; Carsuzaa F; Bellanger Y; Bartier S; Fournier V; Lecron JC; Bainaud M; Louis B; Tringali S; Dufour X; Coste A; Favot L; Bequignon E
Int Forum Allergy Rhinol; 2024 Mar; ():. PubMed ID: 38465788
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of chronic rhinosinusitis with nasal polyps: role of IL-6 in airway epithelial cell dysfunction.
Bequignon E; Mangin D; Bécaud J; Pasquier J; Angely C; Bottier M; Escudier E; Isabey D; Filoche M; Louis B; Papon JF; Coste A
J Transl Med; 2020 Mar; 18(1):136. PubMed ID: 32209102
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps.
Carsuzaa F; Bequignon E; Bartier S; Coste A; Dufour X; Bainaud M; Lecron JC; Louis B; Tringali S; Favot L; Fieux M
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047067
[TBL] [Abstract][Full Text] [Related]
4. Staphylococcus aureus enterotoxin B disrupts nasal epithelial barrier integrity.
Martens K; Seys SF; Alpizar YA; Schrijvers R; Bullens DMA; Breynaert C; Lebeer S; Steelant B
Clin Exp Allergy; 2021 Jan; 51(1):87-98. PubMed ID: 33090566
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
6. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
8.
Martens K; De Boeck I; Jokicevic K; Kiekens F; Farré R; Vanderveken OM; Seys SF; Lebeer S; Hellings PW; Steelant B
Allergy Asthma Immunol Res; 2021 Jul; 13(4):560-575. PubMed ID: 34212544
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
10. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression.
Steelant B; Farré R; Wawrzyniak P; Belmans J; Dekimpe E; Vanheel H; Van Gerven L; Kortekaas Krohn I; Bullens DMA; Ceuppens JL; Akdis CA; Boeckxstaens G; Seys SF; Hellings PW
J Allergy Clin Immunol; 2016 Apr; 137(4):1043-1053.e5. PubMed ID: 26846377
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
12. Circulating T Cell Subsets and ILC2s are Altered in Patients With Chronic Rhinosinusitis With Nasal Polyps After Dupilumab Treatment.
Matsuyama T; Takahashi H; Tada H; Chikamatsu K
Am J Rhinol Allergy; 2023 Jan; 37(1):58-64. PubMed ID: 36214075
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
15. Increased CYR61 expression activates CCND1/c-Myc pathway to promote nasal epithelial cells proliferation in chronic rhinosinusitis with nasal polyps.
Luo C; Zhu Y; Zhou J; Sun X; Zhang S; Tan S; Li Z; Lin H; Zhang W
Clin Immunol; 2023 Feb; 247():109235. PubMed ID: 36681101
[TBL] [Abstract][Full Text] [Related]
16. Hypertonic saline and seawater solutions damage sinonasal epithelial cell air-liquid interface cultures.
Jiao J; Yang J; Li J; Li Y; Zhang L
Int Forum Allergy Rhinol; 2020 Jan; 10(1):59-68. PubMed ID: 31610615
[TBL] [Abstract][Full Text] [Related]
17. Budesonide repairs decreased barrier integrity of eosinophilic nasal polyp epithelial cells caused by PM
Ma S; Xian M; Wang Y; Wang C; Zhang L
Clin Transl Allergy; 2021 Jul; 11(5):e12019. PubMed ID: 34262692
[TBL] [Abstract][Full Text] [Related]
18. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4.
Soyka MB; Wawrzyniak P; Eiwegger T; Holzmann D; Treis A; Wanke K; Kast JI; Akdis CA
J Allergy Clin Immunol; 2012 Nov; 130(5):1087-1096.e10. PubMed ID: 22840853
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase activity is a novel target for epithelial barrier defects in patients with eosinophilic chronic rhinosinusitis with nasal polyps.
Duan S; Han X; Jiao J; Wang M; Li Y; Wang Y; Zhang L
Clin Exp Allergy; 2023 Apr; 53(4):443-454. PubMed ID: 36458367
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Bachert C; Laidlaw TM; Cho SH; Mullol J; Swanson BN; Naimi S; Classe M; Harel S; Jagerschmidt A; Laws E; Ruddy M; Praestgaard A; Amin N; Mannent LP
Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1649-1661. PubMed ID: 37322842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
